Related Experiment Video
Updated: Jun 18, 2026
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
Published on: July 23, 2016
Lipid-based Nano-delivery systems as a promising strategy for the treatment of epilepsy: Current status and
Priya Kannan Varshini1, Arunachalam Divya1, Kumar Sowndharya1
1Sri Shanmugha College of Pharmacy, Sangagiri, India.
Objective:
Epilepsy is a prevalent chronic neurological disorder characterized by abnormal neuronal electrical activity. The primary treatment modality for individuals with epilepsy (PWE) is antiseizure medication (ASM). The multiple potential factors contributing to treatment resistance in epilepsy may be attributed to the inability of ASMs to traverse the blood-brain barrier (BBB). Consequently, it is imperative to identify a solution, and optimally, enhance ASM efficacy.
Method:
Innovative drug delivery technologies have shown improved therapeutic efficacy in the treatment of epilepsy as compared with traditional pharmaceutical treatments. Furthermore, exosomes, neosomes, and phytosomes have received interest as potential next-generation drug delivery platforms, owing to their benefits over semi-synthetic and synthetic alternatives. These systems have demonstrated better bioavailability, tailored distribution, and decreased adverse effects, giving them potential choices for boosting the treatment of numerous disorders.
Results:
Exploring and optimizing novel drug delivery systems could lead to significant advancements in the treatment of drug-resistant epilepsy by enhancing the delivery of ASMs to the brain and overcoming barriers like the BBB. Additionally, further research into the mechanisms of action and potential side effects of these innovative drug delivery systems is crucial for their successful clinical translation in epilepsy treatment.
Significant:
Pharmacokinetics and pharmacodynamic can be used to better customize medicines for specific patients, increase efficacy, and lessen side effects. All things considered, the creation of medication delivery systems based on nanotechnology has enormous potential to transform the treatment of epilepsy and enhance patient outcomes.
Plain Language Summary:
Epilepsy is a common neurological illness treated mostly with antiseizure drugs (ASMs), although treatment resistance is typically connected to the difficulty of ASMs to penetrate the blood-brain barrier (BBB). Innovative drug delivery systems, such as exosomes, neosomes, and phytosomes, offer potential advantages over existing approaches by boosting bioavailability, distribution, and minimizing side effects.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:27Bioavailability Enhancement: Drug Permeability Enhancement